FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Federal Register

FDA Debars Nguyen over Misdemeanor Conviction

Federal Register notice: FDA denies a request for a hearing and issues an order debarring Trang Doan Nguyen for five years from providing services in ...

Federal Register

FDA Approves AstraZeneca NDA for Bydureon BCise

FDA approves an AstraZeneca NDA for Bydureon BCise (exenatide extended-release) injectable suspension, a new formulation designed for an improved once...

Federal Register

AstraZenecas Elavil Not Withdrawn Due to Safety/Effectiveness

Federal Register notice: FDA determines that AstraZenecas Elavil (amitriptyline hydrochloride) oral tablets, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 1...

Medical Devices

FDA Warning Letter to Magellan Diagnostics

FDA issues a Warning Letter to Magellan Diagnostics for modifying versions of two of its blood lead testing systems without the agencys required clear...

Human Drugs

SCA Pharma Recalls Injectables Due to Contamination Concern

SCA Pharmaceuticals recalls all lots of several injectable products because there is a potential for them to contain microbial contamination.

Biologics

Biosimilar Savings Projected at $54 billion Over Next Decade

A new analysis from the RAND Corporation says biosimilar approvals should help cut healthcare spending by $54 billion over the next decade.

Federal Register

FDA Determines Regulatory Review Period for Baxters Obizur

Federal Register notice: FDA determines for patent extension purposes that the regulatory review period for Baxters Obizur is 4,216 days.

Federal Register

Draft Guide for Methylphenidate Hydrochloride ANDAs

Federal Register notice: FDA makes available a new draft guidance for industry on generic methylphenidate hydrochloride oral extended-release tablets.

Federal Register

Regulatory Review Period for Inspire Sleep Apnea Device

FDA determines for patent extension purposes that the regulatory review period for Baxters Obizur is 4,216 days.

Human Drugs

FDA Approves Janssens Simponi Aria for 2 New Indications

FDA approves Janssen Biotechs Simponi Aria (golimumab) for treating adults with active psoriatic arthritis and active ankylosing spondylitis.